Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Item
http://www.wikidata.org/entity/Q39585342
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsThe novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5SDF-1 inhibition targets the bone marrow niche for cancer therapy.The 26S proteasome complex: an attractive target for cancer therapyUbiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.Novel treatment options for Waldenström macroglobulinemiaWaldenström macroglobulinemia: from biology to treatment.HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Novel agents in indolent lymphomas.Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
P2860

Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Item
http://www.wikidata.org/entity/Q39585342
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@en
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@nl
type
label
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@en
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@nl
prefLabel
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@en
Carfilzomib-dependent selectiv ...... ldenstrom's Macroglobulinemia.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Carfilzomib-dependent selectiv ...... aldenstrom's Macroglobulinemia
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-10-2130
P407
P433
P478
P50
P577
P698